-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer. The pre-qualification process is a mechanism...

-The Times of India NEW DELHI: The Indian Medical Association (IMA) has asked its state and local units to raise funds from member doctors to organise conferences and functions instead of seeking sponsorship. According to IMA office-bearers, the decision was taken at a meeting on Wednesday in view of allegations about pharmaceutical companies and the device industry shaping the content and style of medical conferences. "If doctors want to meet at a...

-TheWire.in The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog and the Department of Pharmaceuticals (DoP) may be working in an opposing direction. Documents between October 2016 and April 2017 show the intention of various government arms to...

-The Times of India NEW DELHI: Doctors and public health groups have come together to suggest that the government should phase out branded drugs in a calibrated manner and ban differential pricing under different brands to promote generic drug prescriptions. This comes in the wake of PM Narendra Modi's announcement that the government was working on a legal framework to ensure that doctors mandatorily prescribed low cost generic medicines. Following the PM's...

-The Telegraph New Delhi: The government's price cap on coronary stents has not deterred the health-care industry from continuing to offer hospitals profit opportunities of tens of thousands of rupees on other kinds of stents, concerned doctors and health-care industry representatives said.     The National Pharmaceutical Pricing Authority (NPPA), the government's price regulator, had on February 15 imposed a cap of about Rs 30,000 on coronary stents. But hospitals can continue to...